Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
-
1201
-
1202
-
1203
-
1204
-
1205
-
1206
-
1207
Changes in neural activity were decreased in animals pre-exposed to 5-HT and <i>mod-1</i> mutants when the worms switched their locomotive direction.
Published 2019“…<p>(A–F) the neural activity of the RID changes during the transition periods from backward to forward locomotion (A–C) and from forward to backward locomotion (D–F) in the mock (A: p = 1.5 × 10<sup>−5</sup>; D: p = 5.5 × 10<sup>−13</sup>), 5-HT exposed (B: p = 0.092; E: p = 0.79), and <i>mod-1</i> mutant (C: p = 0.081; F: p = 0.93) groups. …”
-
1208
-
1209
<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling.
Published 2017“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
-
1210
-
1211
-
1212
-
1213
-
1214
-
1215
-
1216
-
1217
Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains
Published 2011“…</p> Human primary cells and human and mouse established cell lines were treated with (TGF-β1) or without (control) 5 ng/ml TGF-β1 for 48 hours. The cells were then harvested and incubated with propidium iodide, and DNA content was determined using a FACS Caliber (Becton-Dickinson). …”
-
1218
List of Included studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1219
The search strategy in three databases.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1220
NIH score.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”